- Sartorius Stedim reported an underlying EBITDA of €564.7 million for the first nine months of 2024, a decrease of 4.9% compared to the previous year.
- The company’s revenue for the same period was €2.03 billion, which is down by 1.9% year-over-year.
- Orders received by the company increased by 7.7%, totaling €1.89 billion.
- The underlying EBITDA margin stood at 27.8%, slightly down from 28.7% the previous year.
- Revenue in constant currency terms declined by 1.3%.
- The forecast for the year includes an underlying EBITDA margin expected to be between 27% and 29%, with an estimate of 28.3%.
- Sartorius Stedim confirms its outlook for 2024, expecting sales revenue to remain around the previous year’s level, with a slight variation from low single-digit negative to low single-digit positive growth.
- Acquisitions are projected to contribute approximately 2% to the sales revenue for the full year.
- Market analysts have rated the stock with 11 buys, 6 holds, and 2 sells.
A look at Sartorius Stedim Biotech Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 2 | |
| Dividend | 2 | |
| Growth | 3 | |
| Resilience | 3 | |
| Momentum | 5 | |
| OVERALL SMART SCORE | 3.0 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
Sartorius Stedim Biotech, a company specializing in laboratory technologies for the pharmaceutical and food industries, has received a mixed bag of Smart Scores in their overall outlook. With a strong momentum score of 5, indicating positive market trends and investor sentiment, the company seems to be positioned well for future growth. Additionally, Sartorius Stedim Biotech scores moderately in growth and resilience, with scores of 3 in both categories. This suggests a certain level of stability and potential for expansion in the long term.
However, the company falls short in value and dividend scores, with ratings of 2 in both aspects. This indicates that investors may find the stock less attractive in terms of its current valuation and dividend payouts. Despite these lower scores, Sartorius Stedim Biotech‘s overall outlook appears solid, especially considering its focus on developing cutting-edge technologies for various sectors. Investors may want to keep an eye on this company for potential future opportunities and growth.
Summary: Sartorius Stedim Biotech develops and manufactures laboratory technologies and equipment for the pharmaceutical and food industries, as well as for public research institutes and laboratories.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
